LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Akebia Therapeutics Inc

Chiusa

SettoreSettore sanitario

3.96 7.32

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.69

Massimo

3.99

Metriche Chiave

By Trading Economics

Entrata

29M

6.1M

Vendite

11M

57M

EPS

0.025

Margine di Profitto

10.66

Dipendenti

181

EBITDA

20M

14M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+82.93% upside

Dividendi

By Dow Jones

Utili prossimi

7 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

242M

854M

Apertura precedente

-3.36

Chiusura precedente

3.96

Notizie sul Sentiment di mercato

By Acuity

50%

50%

166 / 380 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Akebia Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 giu 2025, 14:31 UTC

Utili

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 giu 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

6 giu 2025, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

6 giu 2025, 20:33 UTC

Utili

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 giu 2025, 19:36 UTC

Discorsi di Mercato

Oil Futures Post Solid Weekly Gains -- Market Talk

6 giu 2025, 19:28 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 giu 2025, 18:46 UTC

Discorsi di Mercato

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 giu 2025, 18:02 UTC

Discorsi di Mercato

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 giu 2025, 16:35 UTC

Utili

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 giu 2025, 16:34 UTC

Utili

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 giu 2025, 16:21 UTC

Discorsi di Mercato

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 giu 2025, 16:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

6 giu 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

6 giu 2025, 16:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

6 giu 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

6 giu 2025, 16:07 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

6 giu 2025, 16:07 UTC

Discorsi di Mercato

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 giu 2025, 15:53 UTC

Discorsi di Mercato

Mexican Inflation Seen Rising in May -- Market Talk

6 giu 2025, 15:36 UTC

Discorsi di Mercato

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 giu 2025, 15:36 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

6 giu 2025, 15:33 UTC

Discorsi di Mercato

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 giu 2025, 15:16 UTC

Discorsi di Mercato

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 giu 2025, 15:05 UTC

Discorsi di Mercato

Silver at its Highest In Nearly 15 Years -- Market Talk

6 giu 2025, 14:35 UTC

Discorsi di Mercato

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 giu 2025, 14:28 UTC

Discorsi di Mercato

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 giu 2025, 14:28 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

6 giu 2025, 14:28 UTC

Discorsi di Mercato

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 giu 2025, 14:15 UTC

Discorsi di Mercato

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 giu 2025, 14:12 UTC

Utili

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 giu 2025, 14:09 UTC

Utili

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Confronto tra pari

Modifica del prezzo

Akebia Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

82.93% in crescita

Previsioni per 12 mesi

Media 6.75 USD  82.93%

Alto 8 USD

Basso 6 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Akebia Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

4

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

2.345 / N/ASupporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

166 / 380 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.